CN1264824C - 喹唑啉衍生物 - Google Patents

喹唑啉衍生物 Download PDF

Info

Publication number
CN1264824C
CN1264824C CNB028052609A CN02805260A CN1264824C CN 1264824 C CN1264824 C CN 1264824C CN B028052609 A CNB028052609 A CN B028052609A CN 02805260 A CN02805260 A CN 02805260A CN 1264824 C CN1264824 C CN 1264824C
Authority
CN
China
Prior art keywords
expression
alkyl
hydrogen atom
formula
alkoxyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028052609A
Other languages
English (en)
Chinese (zh)
Other versions
CN1492860A (zh
Inventor
北野靖典
河原英治
铃木毅
阿部大辅
中條雅弘
上田直子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Publication of CN1492860A publication Critical patent/CN1492860A/zh
Application granted granted Critical
Publication of CN1264824C publication Critical patent/CN1264824C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB028052609A 2001-02-21 2002-02-21 喹唑啉衍生物 Expired - Fee Related CN1264824C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP45827/2001 2001-02-21
JP45827/01 2001-02-21
JP2001045827 2001-02-21
JP353525/2001 2001-11-19
JP353525/01 2001-11-19
JP2001353525 2001-11-19

Publications (2)

Publication Number Publication Date
CN1492860A CN1492860A (zh) 2004-04-28
CN1264824C true CN1264824C (zh) 2006-07-19

Family

ID=26609852

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028052609A Expired - Fee Related CN1264824C (zh) 2001-02-21 2002-02-21 喹唑啉衍生物

Country Status (10)

Country Link
US (2) US7294629B2 (https=)
EP (1) EP1369418B1 (https=)
JP (1) JP4285996B2 (https=)
KR (1) KR100861486B1 (https=)
CN (1) CN1264824C (https=)
AT (1) ATE475652T1 (https=)
CA (1) CA2442742A1 (https=)
DE (1) DE60237145D1 (https=)
TW (1) TWI309647B (https=)
WO (1) WO2002066445A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324597B (en) 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
ATE395346T1 (de) 2003-09-16 2008-05-15 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
CN1882570B (zh) * 2003-09-19 2010-12-08 阿斯利康(瑞典)有限公司 喹唑啉衍生物
ES2279441T3 (es) 2003-09-19 2007-08-16 Astrazeneca Ab Derivados de quinazolina.
WO2005030757A1 (en) * 2003-09-25 2005-04-07 Astrazeneca Ab Quinazoline derivatives
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
EP1684762A4 (en) * 2003-11-13 2009-06-17 Ambit Biosciences Corp UREA DERIVATIVES AS MODULATORS OF KINASE
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
WO2005051924A1 (ja) * 2003-11-28 2005-06-09 Mitsubishi Pharma Corporation キナゾリン誘導体及びその製造方法
DE602005010824D1 (de) 2004-02-03 2008-12-18 Astrazeneca Ab Chinazolinderivate
KR20080095915A (ko) 2004-05-06 2008-10-29 워너-램버트 캄파니 엘엘씨 4-페닐아미노-퀴나졸린-6-일-아미드
CN101010304A (zh) * 2004-09-01 2007-08-01 三菱制药株式会社 分子伴侣功能调节剂
ATE501148T1 (de) 2004-12-14 2011-03-15 Astrazeneca Ab Pyrazolopyrimidinverbindungen als antitumormittel
DK1854789T3 (da) * 2005-02-23 2013-10-21 Shionogi & Co Quinazolinderivat med tyrosin-kinase inhibitorisk aktivitet
KR20070107151A (ko) 2005-02-26 2007-11-06 아스트라제네카 아베 티로신 키나제 억제제로서의 퀴나졸린 유도체
WO2006106721A1 (ja) * 2005-03-30 2006-10-12 Shionogi & Co., Ltd. チロシンキナーゼ阻害作用を有するピリミジン誘導体
ATE488513T1 (de) 2005-09-20 2010-12-15 Astrazeneca Ab 4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
JP2009529045A (ja) * 2006-03-03 2009-08-13 アベオ ファーマシューティカルズ， インコーポレイテッド ７−アルキニル−４−アミノキナゾリンを合成する方法及び関連した中間体
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
AU2008212999A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
JP5739802B2 (ja) 2008-05-13 2015-06-24 アストラゼネカ アクチボラグ ４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
BR112012022868A2 (pt) * 2010-03-16 2018-06-05 Merck Patent Gmbh morfolinilquinazolinas
WO2012122058A2 (en) * 2011-03-04 2012-09-13 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
WO2012155339A1 (zh) * 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
WO2013106792A1 (en) 2012-01-13 2013-07-18 Acea Biosciences Inc. Heterocyclic compounds and uses as anticancer agents.
US9586965B2 (en) 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
CN103254143B (zh) * 2013-04-26 2015-10-07 浙江工业大学 4-[4-(2-二乙氨基乙酰氨基)苯胺基]-6-取代喹唑啉类化合物及制备和应用
TWI609012B (zh) 2013-04-28 2017-12-21 廣東東陽光藥業有限公司 氨基喹唑啉類衍生物及其鹽和使用方法
KR102173433B1 (ko) 2013-07-11 2020-11-04 에이시아 바이오사이언시스 인코포레이티드. 키나아제 억제제로써의 피리미딘 유도체
JP6889494B2 (ja) 2015-10-09 2021-06-18 エイシア セラピューティクス， インコーポレイテッド ピロロピリミジンキナーゼ阻害剤の薬学的塩、物理的形態、および組成物、ならびにそれらを作製する方法
WO2018139626A1 (ja) * 2017-01-30 2018-08-02 塩野義製薬株式会社 キナゾリン誘導体を含有する固形製剤
AU2017408099A1 (en) 2017-04-07 2019-11-07 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
CN110577514B (zh) * 2018-06-08 2022-07-05 江苏威凯尔医药科技有限公司 人表皮生长因子受体抑制剂及其制备方法和应用
WO2019233459A1 (zh) * 2018-06-08 2019-12-12 江苏威凯尔医药科技有限公司 人表皮生长因子受体抑制剂及其制备方法和应用
AU2020328598A1 (en) * 2019-08-15 2022-03-03 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3134236B2 (ja) 1992-01-30 2001-02-13 株式会社林原生物化学研究所 α−グリコシル−Ｌ−アスコルビン酸高含有物の製造方法とその製造のための分離システム
JP2994165B2 (ja) 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
EA001595B1 (ru) 1996-04-12 2001-06-25 Варнер-Ламберт Компани Необратимые ингибиторы тирозинкиназ
EP0837063A1 (en) * 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6251912B1 (en) * 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
EP1292591B1 (en) * 2000-06-22 2005-02-02 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth
WO2005051924A1 (ja) * 2003-11-28 2005-06-09 Mitsubishi Pharma Corporation キナゾリン誘導体及びその製造方法

Also Published As

Publication number Publication date
WO2002066445A1 (en) 2002-08-29
KR100861486B1 (ko) 2008-10-02
CN1492860A (zh) 2004-04-28
US7294629B2 (en) 2007-11-13
JPWO2002066445A1 (ja) 2004-06-17
EP1369418B1 (en) 2010-07-28
DE60237145D1 (de) 2010-09-09
CA2442742A1 (en) 2002-08-29
TWI309647B (https=) 2009-05-11
US20040116422A1 (en) 2004-06-17
KR20030086269A (ko) 2003-11-07
EP1369418A1 (en) 2003-12-10
EP1369418A4 (en) 2005-09-14
JP4285996B2 (ja) 2009-06-24
ATE475652T1 (de) 2010-08-15
US20070265260A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
CN1264824C (zh) 喹唑啉衍生物
CN1182123C (zh) 用作抗癌剂的取代的二环衍生物
CN100343238C (zh) 用作抗肿瘤药物的喹唑啉衍生物
CN100339376C (zh) 含氮芳环衍生物
CN1150171C (zh) 二环杂环,含这些化合物的药物组合物,及其制备方法
CN1267431C (zh) 取代的喹唑啉衍生物及其在制备作为抑制剂的药物中的用途
CN1144786C (zh) 作为蛋白质酪氨酸激酶抑制剂的取代的3-氰基喹啉
CN1240688C (zh) 喹唑啉化合物
CN1183111C (zh) 环烷并吲哚和环烷并氮杂吲哚衍生物,其制备方法和含有它们的药物组合物
CN1183114C (zh) 喹啉衍生物及喹唑啉衍生物
CN1166645C (zh) 双环杂环化合物,含有该化合物的药物组合物,该化合物的用途及其制备方法
CN1553899A (zh) 抑制肝细胞生长因子受体自磷酸化的喹啉衍生物和喹唑啉衍生物以及含有这些化合物的药物组合物
CN1179960C (zh) 吲哚衍生物和其在治疗骨质疏松中的应用以及其它应用
CN1642552A (zh) 作为酪氨酸激酶抑制剂的4－(n－苯氨基)－喹唑啉/喹啉
CN1271349A (zh) 取代的喹唑啉衍生物及其作为酪氨酸激酶抑制剂的用途
CN1056140C (zh) 联苯衍生物,它们的制备以及它们在治疗高血压和心脏病方面的应用
CN1060841A (zh) 喹唑啉衍生物及其制备方法
CN1882572A (zh) 作为抗肿瘤药物的喹唑啉衍生物
CN1597667A (zh) 用作血管生成抑制剂的喹唑啉衍生物
CN1341104A (zh) 具有对因酪氨酸激酶引起的信号转导有抑止作用的4′－氨基喹唑啉及喹啉衍生物
CN1620296A (zh) 作为Aurora激酶抑制剂的取代喹唑啉衍生物
CN1107149A (zh) 哌嗪衍生物
CN1809557A (zh) 化合物
CN1137037A (zh) 喹唑啉衍生物
CN1576275A (zh) 用于治疗异常细胞生长的取代的双环衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060719

Termination date: 20110221